Positions

Selected Publications

Academic Article

Year Title Altmetric
2023 Case report: A novel homozygous histidine triad nucleotide-binding protein 1 mutation featuring distal hereditary motor-predominant neuropathy with rimmed vacuoles.  Frontiers in Neurology.  14. 2023
2022 Autonomic neuropathy as post-acute sequela of SARS-CoV-2 infection: a case report.  Journal of NeuroVirology.  28:158-161. 2022
2022 Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyria.  Journal of the American Academy of Dermatology.  2022
2022 Orthostatic intolerance in post-concussion patients 2022
2021 FGF23, a novel muscle biomarker detected in the early stages of ALS.  Scientific Reports.  11. 2021
2021 Fat mass loss correlates with faster disease progression in amyotrophic lateral sclerosis patients: Exploring the utility of dual-energy xray absorptiometry in a prospective study.  PLoS One.  16. 2021
2021 Metabolic syndrome and peripheral neuropathy.  Muscle and Nerve.  63:285-293. 2021
2021 Correction to: Porphyric Neuropathy: Pathophysiology, Diagnosis, and Updated Management (Current Neurology and Neuroscience Reports, (2020), 20, 12, (56), 10.1007/s11910-020-01078-8).  Current Neurology and Neuroscience Reports.  21. 2021
2021 Single-institutional reference values for concentric needle jitter analysis using the extrapolated reference values procedure: Comparison to published reference values.  Muscle and Nerve.  63:113-116. 2021
2020 Porphyric Neuropathy: Pathophysiology, Diagnosis, and Updated Management.  Current Neurology and Neuroscience Reports.  20. 2020
2020 Wnt antagonist FRZB is a muscle biomarker of denervation atrophy in amyotrophic lateral sclerosis.  Scientific Reports.  10. 2020
2020 Consistent improvement with eculizumab across muscle groups in myasthenia gravis.  Annals of Clinical and Translational Neurology.  7:1327-1339. 2020
2020 ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.  Journal of Neurology.  267:1991-2001. 2020
2020 The vitamin D activator CYP27B1 is upregulated in muscle fibers in denervating disease and can track progression in amyotrophic lateral sclerosis 2020
2020 Hereditary Transthyretin Amyloidosis: Clinical Presentation and Management Updates.  Journal of Clinical Neuromuscular Disease.  21:144-156. 2020
2020 Fibulin-5 mutation featuring Charcot-Marie-Tooth disease, joint hyperlaxity, and scoliosis 2020
2019 Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis (Quality of Life Research, (2019), 28, 8, (2247-2254), 10.1007/s11136-019-02148-2).  Quality of Life Research.  28:2255. 2019
2019 Eculizumab improves fatigue in refractory generalized myasthenia gravis.  Quality of Life Research.  28:2247-2254. 2019
2019 Hereditary Sensory and Autonomic Neuropathies: Adding More to the Classification.  Current Neurology and Neuroscience Reports.  19. 2019
2019 Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.  Muscle and Nerve.  60:14-24. 2019
2019 Congenital myopathy with a novel SELN missense mutation and the challenge to differentiate it from congenital muscular dystrophy.  Journal of Clinical Neuroscience.  62:238-239. 2019
2019 Plantar Ulcers and Neuropathic Arthropathies: Associated Diseases, Polyneuropathy Correlates, and Risk Covariates 2019
2018 Muscle microRNA signatures as biomarkers of disease progression in amyotrophic lateral sclerosis.  Neurobiology of Disease.  114:85-94. 2018
2018 Subacute demyelinating polyradiculoneuropathy complicating Epstein–Barr virus infection in GATA2 haploinsufficiency.  Muscle and Nerve.  57:150-156. 2018
2017 Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.  Lancet Neurology.  16:976-986. 2017
2017 History of electromyography and nerve conduction studies: A tribute to the founding fathers.  Journal of Clinical Neuroscience.  43:54-60. 2017
2017 Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis.  PLoS One.  12. 2017
2017 Renaut Corpuscles or Peripheral Nerve Infarcts? A Historical Overview.  Canadian Journal of Neurological Sciences.  44:184-189. 2017
2016 Electromyographic Findings in Gracilis Muscle Grafts Used to Augment Elbow Flexion in Traumatic Brachial Plexopathy.  Journal of Clinical Neurophysiology.  33:549-553. 2016
2016 Clinical spectrum of valosin containing protein (VCP)-opathy.  Muscle and Nerve.  54:94-99. 2016
2016 Clinical and Electrophysiological Findings in Hereditary Inclusion Body Myopathy Compared with Sporadic Inclusion Body Myositis.  Journal of Clinical Neuromuscular Disease.  17:190-196. 2016
2015 Transforming growth factor beta (TGF-β) is a muscle biomarker of disease progression in ALS and correlates with smad expression.  PLoS One.  10. 2015
2015 Charcot Marie Tooth disease (CMT): historical perspectives and evolution.  Journal of Neurology.  262:801-805. 2015
2015 Sensory manifestations of diabetic neuropathies: Anatomical and clinical correlations.  Prosthetics and Orthotics International.  39:7-16. 2015
2014 Smads as muscle biomarkers in amyotrophic lateral sclerosis.  Annals of Clinical and Translational Neurology.  1:778-787. 2014
2014 Novel OPA1 mutation featuring spastic paraparesis and intestinal dysmotility.  Molecular Genetics and Metabolism Reports.  1:443-445. 2014
2013 Epidemiological features of amyotrophic lateral sclerosis in a large clinic-based African American population.  Amyotrophic lateral sclerosis & frontotemporal degeneration.  14:334-337. 2013

Education And Training

  • University of Alabama Birmingham Medical Center Neurology, Residency
  • Mayo Clinic Neurology, Postdoctoral Fellowship
  • Doctor of Medicine, 2001

    • Full Name

  • Mohamed Kazamel